Lyophilisation Europe

Spurred by the growth of the new drugs, the lyophilisation market is projected to reach $5,121.5 million by 2019. With the rising risk of contamination and the need for improved formulation methods of biological products, robust capabilities in lyophilisation and freeze drying methods have become critical for prolonging drug life span whilst maintaining its functionality and preventing it from damage.

Innovation and efficiency is requested at every level making SMi’s 3rd annual European conference on Lyophilisation, the perfect platform to strengthen knowledge in key principles such as PAT and QbD whilst keeping you at the forefront of technological breakthroughs to adapt to a competitive growing industry.

We have worked closely with a leading panel of experts such as Takeda, GSK, Boehringer-Ingelheim, Hovione, Novo Nordisk A/S, Baxter Bioscience and UCB BioPharma, to create an agenda that asks questions such as: What are the fundamentals of freeze drying and how can process development be optimised? How can risk-based approaches be integrated into QbD principles? How is spray drying a viable alternative to lyophilisation for achieving continuous production? How does PAT support scales up processes and to what degree has it been successful? What are the future prospects for continuous production processes?

For further details and to register, visit http://www.lyophilisationconference.com/EPM.